目的：观察玻璃体腔注射康柏西普联合周边视网膜激光治疗缺血型视网膜静脉阻塞继发黄斑水肿(RVO-ME)的疗效。

方法：回顾性病例研究。收集2014-10/2018-11在温州医科大学附属眼视光医院诊断为缺血型RVO-ME的患者39例39眼，其中CRVO患者14例14眼，BRVO患者25例25眼。所有患者均予玻璃体腔注射康柏西普联合周边视网膜激光光凝治疗。分别于治疗前后检测最佳矫正视力(BCVA)和黄斑中心凹厚度(CMT)。

结果：治疗后1、2、3、6mo，本组患者BCVA(0.67±0.49、0.56±0.41、0.62±0.52、0.47±0.40)均较治疗前(0.99±0.57)显著改善(P<0.05)，CMT(299.5±188.1、254.8±127.6、294.1±174.9、228.8±64.45μm)均较治疗前(608.4±214.7μm)显著下降(P<0.05)。治疗后6mo BCVA与治疗前基线BCVA呈正相关(r=0.78，P<0.05)，而与治疗前CMT无明显相关性(r=0.25，P=0.13)。

结论：玻璃体腔注射康柏西普联合周边视网膜激光光凝治疗缺血型RVO-ME疗效确切，可有效改善视力，降低CMT。

METHODS: A retrospective clinical study. Totally 39 patients(39 eyes)were included in this study since 2014-10 to 2018-11, who were diagnosed ischemic RVO-ME in Eye Hospital of Wenzhou Medical University. There were 14 CRVO and 25 BRVO. All patients were given intravitreal conbercept combined with peripheral laser photocoagulation. BCVA, OCT were examined before and after treatment.

RESULTS:BCVA of 1, 2, 3, 6mo(0.67±0.49, 0.56±0.41, 0.62±0.52, 0.47±0.40)after treatment was significantly improved compared to base line(0.99±0.57)(P<0.05). CMT of 1, 2, 3, 6mo(299.5±188.1, 254.8±127.6, 294.1±174.9, 228.8±64.45μm)after treatment was significantly decreased compared to base line(608.4±214.7μm)(P<0.05). BCVA of 6mo was positively correlated with base line BCVA(r=0.78, P<0.05),while there was no correlation with base line CMT(r=0.25, P=0.13).

CONCLUSION: Intravitreal conbercept combined with peripheral laser photocoagulation is a effective approach for ischemic RVO-ME, which can significantly improve BCVA and decrease CMT.